98%
921
2 minutes
20
Background: Blunt aortic injuries (BAIs) are traditionally treated as surgical emergencies, with the majority of repairs performed in an urgent fashion within 24 hours, irrespective of the grade of aortic injury. These patients are often underresuscitated and often have multiple other trauma issues that need to be addressed. This study reviews a single center's experience comparing urgent (<24 hours) thoracic endovascular aneurysm repair (TEVAR) versus delayed (>24 hours) TEVAR for Grade III BAI.
Methods: All patients undergoing TEVAR for BAI at a single institution between March 2004 and March 2014 were reviewed (n = 43). Patients with Grade I, II, or IV aortic injuries as well as those who were repaired with an open procedure or who lacked preoperative imaging were excluded from the analysis. Demographics, intraoperative data, postoperative survival, and complications were compared.
Results: During this period, there were 43 patients with blunt thoracic aortic injury. There were 29 patients with Grade III or higher aortic injuries. Of these 29 patients, 1 declined surgery, 2 were repaired with an open procedure, 10 underwent urgent TEVAR, and 16 had initial observation. Of these 16, 13 underwent TEVAR in a delayed fashion (median, 9 days; range, 2-91 days), and 3 died of non-aortic-related pathology. Comparing the immediate repair group versus the delayed repair group, there were no significant demographic differences. Trauma classification scores were similar, although patients in the delayed group had a higher number of nonaortic injuries. The 30-day survival was similar between the two groups (9 of 10 vs. 12 of 16), with no mortalities caused by aortic pathology in either group.
Conclusion: Watchful waiting may be permissible in patients with Grade III BAI with other associated multisystem trauma. This allows for a repair in a more controlled environment.
Level Of Evidence: Therapeutic study, level V.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TA.0000000000001027 | DOI Listing |
Eur J Obstet Gynecol Reprod Biol
September 2025
Department of Biostatistics, Amrita Institute of Medical Sciences, Ponekkara Rd, Edappally, Kochi, Ernakulam 682041 Kerala, India.
Objective: This study compared the oncological outcomes of Pure Uterine Serous Carcinomas (p-USC) and p53-Abnormal Grade 3 Endometroid Endometrial Tumours (p53 Abn G3-EEC).
Methods: A retrospective study was conducted at Amrita Institute of Medical Sciences from February 1, 2015, to December 31, 2020, analysing patients diagnosed with P-USC and p53 Abn G3-EEC. The primary objective was to compare the 5-year Progression-Free Survival (PFS) between two groups.
Semin Arthritis Rheum
August 2025
Division of Rheumatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA; Department of Quantitative Health Sciences, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Electronic address:
Objectives: We aimed to determine the degree to which a healthy dietary pattern is associated with incident rheumatoid arthritis (RA).
Methods: We registered this systematic review and meta-analysis in PROSPERO (CRD42025645056). Inclusion criteria were validated diet (anti-inflammatory, Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and/or healthy eating index [HEI]); validated RA definition; dietary exposure preceding RA; and randomized controlled trial, cohort, or case-control design.
Pigment Cell Melanoma Res
September 2025
Department of Dermatology, CHU Nice, University Côte D'azur, Nice, France.
The term acquired dermal macular hyperpigmentation (ADMH) was introduced to unify Riehl's melanosis (RM), lichen planus pigmentosus (LPP), and related entities. These are cosmetically distressing pigmentary disorders that pose therapeutic challenges. To investigate the efficacy and safety of oral isotretinoin in treating ADMH, we conducted a muticenter retrospective study of patients with ADMH treated with oral isotretinoin between 2014 and 2024.
View Article and Find Full Text PDFESMO Open
September 2025
Sarah Cannon Research Institute United Kingdom, London, UK. Electronic address:
Background: Antibody-drug conjugates (ADCs) combine targeted monoclonal antibodies with cytotoxic payloads and are an emerging modality in systemic cancer therapy. Thirteen ADCs are Food and Drug Administration approved, with many more in development. However, design and use remain challenging, with issues including on/off-target toxicity, resistance from prior exposure to payload classes, and optimal target/payload selection.
View Article and Find Full Text PDFGynecol Oncol
September 2025
University of Chicago, Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Chicago, IL 60637, USA; University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL 60637, USA.
Objective: To identify associations between race, neighborhood disadvantage, and outcomes in women with stage I-III endometrioid endometrial cancer (EEC) treated at a tertiary referral center.
Methods: This retrospective tumor registry study included patients with stage I-III EEC between 1/2006 and 12/2022. Progression-free (PFS) and overall survival (OS) were analyzed by race and neighborhood disadvantage, stratified by Area Deprivation Index (ADI; national quartile).